EGFR and lung cancer: In detail, research has revealed that ginsenoside Rg3 disrupts the cell cycle at G0/G1 phase via the EGFR/Ras/Raf/MEK/ERK pathway in lung cancer (A549), liver cancer (Hep G2) cells, and the formation of Cyclin D1, CDK2, and CDK4 in colon cancer (SW620 and LoVo) cells [649, 650].